Purchase Order 75F40125P00216
- Not listed
- This is a $1,251,731.00 firm fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract, which has no set-aside designation, is part of Task Order 2 under a larger contract vehicle and is focused on examining the influence of synthetic cooling agents on cigarette sensory and subjective effects, as well as use behavior. Lovelace Biomedical Research...
- This federal contract award, valued at $1,403,705.20, was issued by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The contract is a delivery order issued under the Tobacco Products Pharmacology Study master indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. The contract does not have a set-aside designation. LBERI, a non-profit contract research organization,...
- This is a firm fixed-price delivery order awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $3,872,713 task order, which is not set aside, is for a study to evaluate whether reductions in biomarkers of exposure, biomarkers of potential harm, and other health risk markers are proportional to reductions in cigarette smoking when switching to electronic nicotine delivery systems. Lovelace...
- This is a firm fixed-price delivery order issued by the Department of Health and Human Services Food and Drug Administration under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery/indefinite quantity (IDIQ) contract. The $1,408,956.00 task order was awarded to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to perform detection and characterization of DNA adducts generated by tobacco flavorants in aerosol...
- This firm fixed-price delivery order was awarded by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The $2,472,244.00 contract is for the evaluation of e-cigarette aerosol in in vivo nonclinical models and was issued under the In Vivo Toxicology of Tobacco 2015-2020 indefinite delivery, indefinite quantity (IDIQ) contract. Lovelace Biomedical Research Institute has...
- This is a delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a non-profit research organization, to develop a standard guideline protocol for rodent tobacco smoke inhalation studies. The contract has a ceiling value of $1,373,599.00 and is a firm fixed-price task order issued under the "In Vivo Toxicology of Tobacco 2015-2020" indefinite-delivery, indefinite-quantity (IDIQ) contract. The...
- This is a firm fixed-price delivery order awarded by the Department of Health and Human Services Food and Drug Administration to Lovelace Biomedical Research Institute, a not-for-profit contract research organization. The contract has a potential value of $1,835,595.00 and is for a study to investigate the subjective effects and nicotine pharmacokinetics of mentholated smokeless tobacco products in current users. The contract is part of a larger Tobacco Products Pharmacology Study indefinite...
- This is a $897,471 firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), doing business as Inhalation Toxicology Research Institute. The contract is part of a larger In Vivo Toxicology of Tobacco 2015-2020 indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. LBERI, a non-profit contract research organization, will provide preclinical research services to support the...
- This is a firm-fixed-price delivery order contract awarded by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a not-for-profit contract research organization, to conduct in vitro evaluation of the toxic profiles of tobacco additives in a systematic tiered approach. The contract has a ceiling value of $1,552,162.00 and an ultimate completion date of July 14, 2018. It was issued under the FDA's "In Vivo Toxicology of Tobacco...
- The Food and Drug Administration (FDA) awarded a $46,048,623.38 firm fixed-price contract to the Lovelace Biomedical Research Institute to conduct a study on the toxicity of e-cigarette aerosols in in vivo nonclinical models. This contract, which does not have a set-aside designation, supports the FDA's Center for Tobacco Products (CTP) in evaluating e-cigarette products. Lovelace Biomedical Research Institute is a not-for-profit preclinical contract research organization that provides...
This is a sole source, firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization located in Albuquerque, New Mexico. The 24-month contract, valued at $7,058,881.75, is for the completion of toxicological studies for the FDA's Center for Tobacco Products. The award is not set aside for any small business category. Lovelace Biomedical Research Institute has significant experience providing comprehensive research and development services to federal agencies, including animal studies, analytical testing, and preclinical product development across various therapeutic areas. The organization holds multiple Indefinite Delivery/Indefinite Quantity (IDIQ) contracts with agencies such as the National Institutes of Health, Office of the Assistant Secretary for Preparedness and Response, and National Institute on Drug Abuse, demonstrating its versatility in supporting complex federal research and development needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.1m | 9/19/25 |